RxDoctor Payments Data

Neil Strickman, MD

Cardiovascular Disease · Houston, TXNPI 1821190067

Payments from drug & device makers

$76,861in general payments, 2019–2025

Across 654 payments — averaging $117.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • Intact Vascular, Inc.$18K
  • Edwards Lifesciences$6K
  • Silk Road Medical, Inc.$4K
  • Penumbra, Inc.$3K
  • Boston Scientific$1K
  • plus $13K from 43 others
$13,898in research payments, 2019–2025

Across 5 payments — averaging $2779.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$14K

What the payments were for

  • Consulting fees$7,54413%
  • Speaking & faculty fees$9,55017%
  • Travel & lodging$18,19732%
  • Food & beverage$21,74738%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,861 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$278,043
Medicare patients
447
Services billed
1,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$169,353
EntrestoSacubitril/Valsartan29$51,723
JardianceEmpagliflozin24$33,584
Repatha SureclickEvolocumab34$31,290
XareltoRivaroxaban22$22,232
ClopidogrelClopidogrel Bisulfate370$4,489
Metoprolol Succinate280$4,487
Atorvastatin Calcium166$1,993
Nifedipine ErNifedipine40$1,878
Ezetimibe50$1,633
Valsartan66$1,616
Rosuvastatin Calcium126$1,402
Ranolazine ErRanolazine13$1,371
Prasugrel Hcl19$1,359
Losartan Potassium98$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$805$169,353151 claims
NovartisEntresto$610$51,72329 claims
Boehringer IngelheimJardiance$116$33,58424 claims
Johnson & JohnsonXarelto$240$22,23222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →